Pharmaceutics

Preparation of liposomal brucine and its pharmaceutical/pharmacodynamic characterization

Article metrics

Abstract

Aim:

To prepare a novel transdermal preparation of liposomal brucine (LB) and investigate its pharmaceutical/pharmacodynamic characterization.

Methods:

LB was prepared by a modified ethanol-dripping method. Its drug encapsulation efficiency (EE), particle size, in vitro release, and skin permeation were studied. Furthermore, a safety evaluation and pharmacodynamic analysis of LB, including acute dermal toxicity, skin irritation, and analgesic and anti-inflammatory effects were investigated.

Results:

the EE of LB was 72% and the mean particle size of the liposomes was 55.4 nm. The in vitro release profile indicated that less than 68% of the encapsulated brucine was released in 10 h. A skin permeation study showed that compared with the free brucine, LB exhibited higher cumulative drug permeation through the skin and lower drug accumulation in skin tissue, indicative of an obvious promotion of skin permeation with liposomal encapsulation. The acute dermal LD50 of LB was greater than 100 mg/kg (brucine content) and skin irritation tests revealed that LB had no irritation to both integrity and broken skin. A pharmacodynamic evaluation of LB was performed by xylene-induced mouse ear edema test and acetic acid-induced writhing test at the dosage of 1.5, 3, and 6 mg/kg, respectively. The results showed that anti-inflammatory activities and analgesic effects of brucine encapsulated were significantly higher than that of the free brucine (P<0.01). Moreover, LB maintained a remarkably longer anti-inflammatory and analgesic duration.

Conclusion:

It can be proposed that LB prepared here could represent a safe, effective and promising transdermal formulation for analgesic and anti-inflammatory effects.

References

  1. 1

    Chinese Pharmacopoeia Committee. Pharmacopoeia of the People's Republic of China Volume I. Beijing: Chemical Industry Press; 2005.

  2. 2

    Yin W, Wang TS, Yin FZ, Cai BC . Analgesic and anti-inflammatory properties of brucine and brucine N-oxide extracted from seeds of Strychnos nux-vomica. J Ethnopharmacol 2003; 88: 205–14.

  3. 3

    Zhu YN, Bao MZ, Chen D, Liu H, Li JT, Yan HT, et al. Study on the toxicity of brucine in mice. Henan Med Res 1994; 3: 107–9. Chinese.

  4. 4

    Torchilin V, Weissing, V Liposomes (A Practical Approach). Oxford: IRL Press/Oxford University Press; 1990.

  5. 5

    Srinath P, Vyas SP, Diwan PV . Preparation and pharmacodynamic evaluation of liposomes of indomethacin. Drug Dev Ind Pharm 2000; 26: 313–21.

  6. 6

    Singh AK, Das J . Liposome encapsulated vitamin A compounds exhibit greater stability and diminished toxicity. Biophys Chem 1998; 73: 155–62.

  7. 7

    Atif A, Krishna KP, Farhan JA, Yashomati D, Zeenat IK, Divya V . Comparative efficacy of liposome-entrapped amiloride and free amiloride in animal models of seizures and serum potassium in mice. Eur Neuropsychopharmacol 2007; 17: 227–9.

  8. 8

    Schmid MH, Korting HC . Liposomes: a drug carrier system for topical treatment in dermatology. Crit Rev Ther Drug Carrier Syst 1994; 11: 97–118.

  9. 9

    Touitou E, Junginger HE, Weiner ND, Nagai N, Mezei M . Lipo-somes as carriers for topical and transdermal delivery. Int J Pharm 1994; 83: 1189–203.

  10. 10

    Zhang GF, Zhu JB, Zhuang Y, Hu J . Study on optimize the preparation and formulation of nimodipine-containing nanolipo-some. J Chin Pharm Univ 2003; 34: 25–8.

  11. 11

    Lboutounne H, Guillaume YC, Michel L, Makki S, Humbert PH, Millet J . Study and development of encapsulated form of 4, 5, 8-trimethylpsoralen for topical drug delivery. Drug Dev Res 2004; 61: 86–94.

  12. 12

    Isbrucker RA, Edwards JA, Wolz E, Davidovich A, Bausch J . Safety studies on epigallocatechin gallate (EGCG) preparations. Part 2: Dermal, acute and short-term toxicity studies. Food Chem Toxicol 2006; 44: 636–50.

  13. 13

    Michael S, Taharat Y, Anthony EK, Aimee LL, Jason B, Karrie AB, et al. Safety and toxicological evaluation of a novel niacin-bound chromium (III) complex. J Inorg Biochem 2005; 99: 2161–83.

  14. 14

    Tang, XC, Lin, ZG, Cai, W, Chen, N, Shen L . Anti-inflammatory effect of 3-acetylaconitine. Acta Pharmacol Sin 1984; 5: 85–9.

  15. 15

    Koster R, Anderson M, De Beer EJ . Acetic acid for analgesic screening. Fed Proc 1959; 18: 412–6.

  16. 16

    Verma DD, Verma S, Blume G, Fahr A . Particle size of liposomes influences dermal delivery of substances into skin. Int J Pharm 2003; 258: 141–51.

Download references

Author information

Correspondence to Chang-sheng Liu.

Additional information

Project supported by Shanghai Nanotechnology Special Foundation (No 0352nm115 and No 0552nm007).

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Qin, X., Yuan, Y., Liu, C. et al. Preparation of liposomal brucine and its pharmaceutical/pharmacodynamic characterization. Acta Pharmacol Sin 28, 1851–1858 (2007) doi:10.1111/j.1745-7254.2007.00654.x

Download citation

Keywords

  • liposomal brucine
  • transdermal formulation
  • attenuation
  • synergia
  • sustained release
  • analgesic
  • anti-inflammatory

Further reading